Trial Profile
A six-week, fixed dose, double-blind, double-dummy, placebo and sertraline controlled, multicentre trial to evaluate the safety and efficacy of CP-316 311 in outpatients with major depressive disorder
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Nov 2009
Price :
$35
*
At a glance
- Drugs CP 316311 (Primary) ; Sertraline
- Indications Depression; Major depressive disorder
- Focus Therapeutic Use
- 06 Nov 2005 New trial record.